Search research articles
Contact Us
Filters
Showing results (111-120 of 310) with videos related to
Page
of 31
Sort By:
Cancer
|
December 29, 2015
Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project
Daria Thompson, Kieuhoa T Vo, Wendy B London, et al.
Cancer
|
October 9, 2009
Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group
Howard M Katzenstein, Kay W Chang, Mark Krailo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2006
Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study
Lisa A Moreau, Patrick McGrady, Wendy B London, et al.
Pediatric Blood & Cancer
|
March 21, 2009
Influence of neuroblastoma stage on serum-based detection of MYCN amplification
Valerie Combaret, Michael D Hogarty, Wendy B London, et al.
Protein Engineering, Design & Selection : PEDS
|
February 13, 2019
Tag-on-Demand: exploiting amber codon suppression technology for the enrichment of high-expressing membrane protein cell lines
Zachary T Britton, Timothy B London, Jeffrey Carrell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2008
Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database
Rochelle Bagatell, Maja Beck-Popovic, Wendy B London, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2006
Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study
Neyssa Marina, Wendy B London, A Lindsay Frazier, et al.
Frontiers in Oral Health
|
January 20, 2022
The Path to an Evidence-Based Treatment Protocol for Extraoral Photobiomodulation Therapy for the Prevention of Oral Mucositis
Ather Adnan, Anna N Yaroslavsky, James D Carroll, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 13, 2009
Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: rs1800795 (promoter) and rs8192284 (receptor)
Joanne P Lagmay, Wendy B London, Thomas G Gross, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2005
Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study
Rani E George, Wendy B London, Susan L Cohn, et al.
Page
of 31
Search research articles
Search
Showing results (111-120 of 310) with videos related to
Sort By:
Page
of 31
Cancer
|
December 29, 2015
Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project
Daria Thompson, Kieuhoa T Vo, Wendy B London, et al.
Cancer
|
October 9, 2009
Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group
Howard M Katzenstein, Kay W Chang, Mark Krailo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2006
Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study
Lisa A Moreau, Patrick McGrady, Wendy B London, et al.
Pediatric Blood & Cancer
|
March 21, 2009
Influence of neuroblastoma stage on serum-based detection of MYCN amplification
Valerie Combaret, Michael D Hogarty, Wendy B London, et al.
Protein Engineering, Design & Selection : PEDS
|
February 13, 2019
Tag-on-Demand: exploiting amber codon suppression technology for the enrichment of high-expressing membrane protein cell lines
Zachary T Britton, Timothy B London, Jeffrey Carrell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2008
Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database
Rochelle Bagatell, Maja Beck-Popovic, Wendy B London, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2006
Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study
Neyssa Marina, Wendy B London, A Lindsay Frazier, et al.
Frontiers in Oral Health
|
January 20, 2022
The Path to an Evidence-Based Treatment Protocol for Extraoral Photobiomodulation Therapy for the Prevention of Oral Mucositis
Ather Adnan, Anna N Yaroslavsky, James D Carroll, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 13, 2009
Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: rs1800795 (promoter) and rs8192284 (receptor)
Joanne P Lagmay, Wendy B London, Thomas G Gross, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2005
Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study
Rani E George, Wendy B London, Susan L Cohn, et al.
Page
of 31